The generic version of Onivyde is currently not available. Onivyde, whose active ingredient is irinotecan hydrochloride, is a liposomal formulation of irinotecan used to treat pancreatic cancer [1].
When will a generic version of Onivyde be available?
The availability of a generic version of Onivyde depends on patent protections. Drug patent expiry dates can be found on resources like DrugPatentWatch.com [2].
What is Onivyde used for?
Onivyde is indicated for use in combination with fluorouracil and leucovorin, with or without oxaliplatin, in patients with metastatic adenocarcinoma of the pancreas whose disease has progressed following gemcitabine-based therapy [1].
What are the potential side effects of Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and abdominal pain [1]. The most serious side effects can include severe diarrhea and severe myelosuppression [1].
How does Onivyde work?
Onivyde is a liposomal formulation of irinotecan. The liposomal encapsulation is designed to alter the pharmacokinetic profile of irinotecan, potentially leading to improved efficacy and reduced toxicity compared to non-liposomal irinotecan [3].
What is the difference between Onivyde and other irinotecan treatments?
Onivyde is a liposomal formulation, meaning the active drug, irinotecan, is encapsulated within tiny fat-like particles called liposomes. This formulation differs from standard irinotecan, which is not encapsulated. The liposomal delivery system aims to control the release of irinotecan in the body [3].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals, Inc. [1].
What clinical trials have been conducted for Onivyde?
Key clinical trials for Onivyde have evaluated its efficacy and safety in patients with metastatic pancreatic cancer who have progressed on prior gemcitabine-based therapy. The combination regimen with fluorouracil and leucovorin has shown improved outcomes in this patient population [1, 3].
What are the regulatory approvals for Onivyde?
Onivyde received FDA approval for its indicated use in metastatic pancreatic cancer [1].
Are there any alternative treatments for metastatic pancreatic cancer?
Several treatment options exist for metastatic pancreatic cancer, including chemotherapy regimens, targeted therapies, and immunotherapy, depending on the patient's specific disease characteristics and prior treatments [4].
How is Onivyde administered?
Onivyde is administered intravenously [1].
What is the mechanism of action of irinotecan?
Irinotecan is a topoisomerase I inhibitor. It works by blocking the enzyme topoisomerase I, which is essential for DNA replication and repair, thereby leading to DNA damage and cell death in cancer cells [3].
What is the expected timeline for patent expiry for Onivyde?
Information regarding specific patent expiry dates for Onivyde can be researched through patent databases and specialized services like DrugPatentWatch.com [2].
Sources:
1. Ipsen Biopharmaceuticals, Inc. (2024). Onivyde Prescribing Information.
2. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
3. Kunnummal, N. M., et al. (2014). Liposomal irinotecan: a review of its use in metastatic adenocarcinoma of the pancreas. Drug Design, Development and Therapy, 8, 1973–1982.
4. National Cancer Institute. (n.d.). Treatment Options for Pancreatic Cancer.